Evidence map›Paper›PMID 20803699›Full record

ReviewInflammatory bowel diseases2010

Toll-like receptors in inflammatory bowel diseases: a decade later.

Elke Cario

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Inflammatory bowel diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02952131 (Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease), which is not on this map. Cited by 154 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 4 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02952131 phase1 / phase2suspendednot on this mapstarted 2016, after this paper: background citation

Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

TypeinterventionalSponsorHealeon Medical IncRan2016 to 2026Enrolled100ConditionsInflammatory Bowel DiseasesArmsLipoaspiration, AD-cSVF, Normal Saline IV
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 4 syntheses or guidelines pooled it, 332 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Elke CarioDivision of Gastroenterology & Hepatology, University Hospital of Essen, and Medical School, University of Duisburg-Essen, Essen, Germany. elke.cario@uni-due.de
University of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differential alteration of Toll-like receptor (TLR) expression in inflammatory bowel disease (IBD) was first described 10 years ago. Since then, studies from many groups have led to the current concept that TLRs represent key mediators of innate host defense in the intestine, involved in maintaining mucosal as well as commensal homeostasis. Recent findings in diverse murine models of colitis have helped to reveal the mechanistic importance of TLR dysfunction in IBD pathogenesis. It has become evident that environment, genetics, and host immunity form a multidimensional and highly interactive regulatory triad that controls TLR function in the intestinal mucosa. Imbalanced relationships within this triad may promote aberrant TLR signaling, critically contributing to acute and chronic intestinal inflammatory processes in IBD colitis and associated cancer.

Indexed as

AnimalsHumansInflammatory Bowel DiseasesToll-Like ReceptorsToll-Like Receptors

Identifiers

PMID20803699
PMCPMC2958454
OpenAlexW2043202073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.